If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

Now, a combination of Tagrisso with another drug looks like it may help tackle that issue. The most common biomarker among people with EGFR-mutated lung cancer who develop resistance to targeted ...

Tagrisso (osimertinib) is a brand-name oral tablet that’s prescribed for certain adults with non-small cell lung cancer (NSCLC). The cost of the drug with and without insurance can depend on ...

Rybrevant is a bispecific antibody injection targeting EGFR and MET, while lazertinib is an oral third-generation EGFR tyrosine kinase inhibitor like Tagrisso, which is AZ’s top-selling drug ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung cancer. The regulatory body has approved Tagrisso for the treatment of ...

In 2023, TAGRISSO® plus ORPATHYS® received Fast Track designation from the US Food and Drug Administration (FDA) in this setting. ORPATHYS® is an oral, potent, and highly selective MET tyrosine ...